ISMP Medication Safety Alert!®

Community/Ambulatory

A valuable resource to reduce medication error risk in outpatient settings

The ISMP Medication Safety Alert!®Community/Ambulatory Care is a digital newsletter, published monthly for healthcare practitioners in ambulatory settings, including community pharmacies, specialty pharmacies, outpatient clinics, physician offices, and state institutions.

Who reads this newsletter?

  • Community/ambulatory/specialty care pharmacists
  • Pharmacy managers and executives
  • Pharmacy technicians and other pharmacy staff
  • Physicians and nurses in ambulatory practice
  • Anyone concerned with medication safety

Subscription Options

Online access to twelve (12) issues per year. You will receive a reminder notice via email to renew your annual subscription before your subscription expires. Your subscription will not automatically renew.
Single issues are available for purchase. 

Academic-based subscription: contact ISMP for pricing

Pharmaceutical Industry (and other healthcare related companies): contact ISMP for pricing

Chain Pharmacies & Multi Site organizations: contact ISMP for pricing


 

Personal Subscription

Subscription Information

  • $70.00 per year

  • Online access for one (1) user

  • No redistribution is permitted

Single Site Subscription

Subscription Information for healthcare organizations (e.g. hospitals, clinics, pharmacies)

  • $100.00 per year

  • Online access for up to 50 users within a single site organization

  • Permission to redistribute within single-site location 

  • Instructions to add users to a subscription will be emailed to the user purchasing the subscription

  • Please use your organization email address when subscribing

  • Chain pharmacies/Multi-site organizations: Contact ISMP for pricing

Browse Issues

This month's main topic: QuarterWatchTM (includes new data from Quarter 4, 2018 and Quarter 1, 2019): Focus on Four New Drugs: Xofluza, Aimovig, Ajovy, and Emgality
This month's main topic: ISMP National Vaccine Errors Reporting Program 2017 Analysis: Vaccine Errors Continue with Little Change
This month's main topic: QuarterWatch™ (Quarter 3 2017): Emerging Risks with Inhaled Medications Using the Ellipta Device, the Controversy with Antidepressants, and Loperamide Abuse